July 15, 2025

Data from Mechanism of Initial Favorable Response to Decitabine in TP53-Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase II trial featured decitabine treatment in MDS and AML patients, revealing immune activation and relapse mechanisms related to tp53 mutations.

Patients with myelodysplastic syndrome and acute myeloid leukemia showed responses to decitabine, associated with tp53 mutations.
Integrative analysis explored immune and leukemic cell dynamics during decitabine treatment and relapse stages.
Single-cell transcriptomics confirmed immune activation specifically in tp53-mutated patients post-decitabine.
Findings help to understand the relapse mechanisms and immune interactions in response to decitabine therapy.

Ng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase II trial featured decitabine treatment in MDS and AML patients, revealing immune activation and relapse mechanisms related to tp53 mutations.